부산대학교 도서관

At 6 months follow-up, the disease remained well-controlled for 2/3 patients, whereas 1/3 patient had a disease flare 9 months after the ofatumumab course and received a second course with good response. In this small series, treatment with ofatumumab for patients with jSLE allergic to rituximab was a safe, well-tolerated and effective alternative to rituximab therapy for B cell depletion. Sir, Rituximab, a chimeric monoclonal antibody (mAb) that specifically targets CD20-positive B cells, is an evolving therapy which has been used in refractory juvenile systemic lupus erythematosus (SLE). [Extracted from the article]